Skip to content
Cart
Menu

Research

Published findings, in context.

Each finding is shown with the evidence level at which it was observed. A result in an animal model or in cell culture is not a result in humans.

Topic

All topicsTissue damage modelsExtracellular matrixCell signalingCerebral ischemia modelsDermal fibroblasts

Evidence level

All levelsIn vitroAnimalHuman, observationalHuman, controlledReview
More filters (study type, organism, year)

Study type

All typesIn vitro studyAnimal studyObservational (human)Controlled (human)Systematic reviewNarrative reviewCase report
Publication year

1 publication

Compounds filed under Cell signaling · Human, controlled

  • Human, controlledControlled study in humans· Homo sapiens

    Randomized, double-blind, placebo-controlled 48-week trial in 338 adults: endpoints not summarized in this profile

    The New England Journal of Medicine2023PMID 37366315 (opens PubMed in a new tab)Full record on PubMedDOI 10.1056/NEJMoa2301972 (opens the publisher record in a new tab)

    Filed under GLP-3

    Model
    Randomized, double-blind, placebo-controlled trial of 48 weeks in 338 adults, with several exposure groups and a placebo group; registered as NCT04881760
    Sample size
    338
    Exposure
    Retatrutide, several exposure groups
    Comparator
    Placebo

    Trial funded by the developer, with company employees among the authors, conducted with material supplied by the developer. Its primary and secondary endpoints are not summarized in this profile; they are described in the original record. The authors report that the most common adverse events were gastrointestinal, occurred more often in higher-exposure groups and were mostly mild to moderate, and that heart rate increased with exposure, peaking at 24 weeks and declining thereafter.

For laboratory research use only. Not for human or veterinary use or consumption. Not for diagnostic use. Not evaluated by the U.S. FDA.